From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease

Paediatrics and Child Health

Volumn 16, Issue 8, 2011, Pages

  Major, Maria ^a   Moss, Steven ^b   Gold, Ronald ^b  

^a Novartis Vaccines and Diagnostics   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Meningococcal disease; Meningococcal vaccine; Neisseria meningitidis; Serogroup B meningococcus

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; COMPLEMENT FACTOR H; MENINGOCOCCUS VACCINE; NEISSERIA HEPARIN BINDING ANTIGEN; NEISSERIAL ADHESIN A; PORIN A; UNCLASSIFIED DRUG;

ANTIBODY TITER; BACTERIAL STRAIN; CANADA; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GENE IDENTIFICATION; GENETIC ANALYSIS; HEADACHE; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MALAISE; MEMBRANE VESICLE; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; MYALGIA; NEISSERIA MENINGITIDIS; NONHUMAN; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 80053926739     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/16.8.e61     Document Type: Review

References (32)

1. National Advisory Committee on Immunization. Update on the invasive meningococcal disease and meningococcal disease and meningococcal vaccine conjugate recommendations. Can Commun Dis Rep 2009;35:1-40.
2. Stephens DS, Greenwood B, Brandzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007;369:2196-210. (Pubitemid 46977462)
3. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998;26:1159-64. (Pubitemid 28215481)
4. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths IUK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: A systematic review and meta-analysis. Lancet Infect Dis 2010;10:317-28.
5. Guiver M, Borrow R, Marsh J, et al. Evaluation of the Applied Biosystems automated Taqman polymerase chain reaction system for the detection of meningococcal DNA. FEMS Immunol Med Microbiol 2000;28:173-9. (Pubitemid 30224639)
6. Richardson DC, Louie L, Louie M, Simor AE. Evaluation of a rapid PCR assay for diagnosis of meningococcal meningitis. J Clin Microbiol 2003;41:385-3.
7. Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 2009;9:418-27.
8. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotshlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: Prospects for routine immunization of infants and children. J Infect Dis 1979;140:690-7. (Pubitemid 10214192)
9. De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: A 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011;30:1-4.
10. Ehrlich TR, Von Rosenstiel IA, Grootenhuis MA, Gerrits AI, Bos AP. Long-term psychological distress in parents of child survivors of severe meningococcal disease. Pediatr Rehabil 2005;8:220-4. (Pubitemid 40978685)
11. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. BMJ 2003;326:365-6. (Pubitemid 36241472)
12. Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43. (Pubitemid 351364476)
13. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009;27S:B3-12.
14. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287;1816-20.
15. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010;50(Suppl 2):S54-65.
16. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines - an unfinished story. Lancet Infect Dis 2010;10:112-24.
17. Su, EL, Snape MD. A combination recombinant and protein outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines 2011;10:575-88.
18. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin infect Dis 2010;51:1127-37.
19. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization - international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006;24:5093-107. (Pubitemid 44209069)
20. Van Alphen L, van den Dobbelsteen G. Meningococcal B vaccine development and evaluation of efficacy. Hum Vaccin 2008;4:158-61. (Pubitemid 351881185)
21. Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis 2009;49:597-605.
22. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129:1307-26.
23. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010;107:19490-5.
24. Gossger N, Snape MD, Finn A, et al. Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) administered with or without routine infant vaccinations in different schedules. The 29th European Society for Paediatric Infectious Diseases Conference. The Hague, The Netherlands, June 7 to 11, 2011. (Abst P1205). 〈www.abstractserver.com/ ESPID2011/planner/index.php?go=abstract&action=abstract-iplanner&absno= 1205&ESPID2011=e35lhd9l9cblkjupn8758m5e85&ESPID2011= e35lhd9l9cblkjupn8758m5e85〉 (Accessed on August 29, 2011).
25. Vesikari T, Prymula R, Liese J, et al. Booster dose at 12 months of an investigational meningococcal serogroup B vaccine (4CMenB) in healthy toddlers previously primed at 2,4,6 months. The 29th European Society for Paediatric Infectious Diseases Conference. The Hague, The Netherlands, June 7 to 11, 2011. (Abst P.877). 〈www.abstractserver.com/ESPID2011/planner/index.php?go= abstract&action=abstract-iplanner&absno=877&ESPID20 11=fa0soivq1ef3ets5d9jad8miu0&ESPID2011=fa0soivq1ef3ets5d9jad8miu0〉 (Accessed on August 29, 2011).
26. Prymula R, Vesikari T, Esposito S, et al. Catch-up vaccination of healthy toddlers with an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) - exploration of a two-dose schedule. The 29th European Society for Paediatric Infectious Diseases Conference. The Hague, The Netherlands, June 7 to 11, 2011. (Abst P900). 〈www.abstractserver.com/ESPID2011/planner/ index.php?go=abstract&action=abstract-iplanner&absno=900&ESPID2011= tphm8f4kv1mmkobjonbmht5kt7&ESPID2011=tphm8f4kv1mmkobjonbmht5kt7〉 (Accessed on August 29, 2011).
27. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of an investigational multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents. The 29th European Society for Paediatric Infectious Diseases Conference. The Hague, The Netherlands, June 7 to 11, 2011. (Abst P.905). 〈www.abstractserver.com/ESPID2011/planner/index. php?go=abstract&action=abstract-iplanner&absno=905&ESPID2011= fa0soivq1ef3ets5d9jad8miu0&ESPID2011=fa0soivq1ef3ets5d9jad8miu0〉 (Accessed on August 29, 2011).
28. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011;18:483-6.
29. Beeretz I, Snape MD, Finn A, et al. Reactogenicity and safety of multicomponent meningococcal serogroup B vaccine (4CMenB) administered with or without routine infant vaccinations in different schedules. The 29th European Society for Paediatric Infectious Diseases Conference. The Hague, The Netherlands, June 7 to 11, 2011. (Abst P1187). 〈www.abstractserver.com/ ESPID2011/planner/index.php?go=abstract&action=abstract-iplanner&absno= 1187&ESPID2011=e35lhd9l9cblkjupn8758m5e85&ESPID2011=e35lhd9l9cbl kjupn8758m5e85〉 (Accessed on August 29, 2011).
30. Esposito, S, Vesikari T, Kimura A, et al. Tolerability of a three-dose schedule of an investigational multicomponent meningococcal serogroup B vaccine and routine vaccines in a lot consistency trial. The 17th International Pathogenic Neisseria Conference. Banff, September 11 to 16, 2010. (Abst P182). 〈http://neisseria.org/ipnc/2010/IPNC-2010-abstracts.pdf〉 (Accessed on August 29, 2011).
31. Prymula R, Esposito S, Kittel C, et al. Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunizations. The 29th European Society for Paediatric Infectious Diseases Conference. The Hague, The Netherlands, June 7 to 11, 2011. (Abst P1410). 〈www. abstractserver.com/espid2011/planner/index.php?go=abstract&action= abstract-iplanner&absno=1410&ESPID2011=28f4t2k9177vnaphro41durd02& ESPID2011=28f4t2k9177vnaphro41durd02〉 (Accessed on August 29, 2011).
32. Mothibeli KM, du Plessis M, von Gottberg A. Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine 2011;29:2187-92.